News & Events

Dec 20, 2011 BV 4 Porfolio Company ForteBio, Inc. Enters Agreement to be Acquired by Pall Corp.
Dec 07, 2011 BV 5 Portfolio Company Aratana Therapeutics Completes $15 Million Series B Financing | Download PDF version
Nov 21, 2011 BV 3 Portfolio Company Portola Pharmaceuticals Announces Completion of $89 Million Financing | Download PDF version
Oct 31, 2011 BV 4 Portfolio Company Pacira Pharmaceuticals, Inc. Announces U.S. FDA Approval of EXPAREL(TM) For Postsurgical Pain Management
Oct 27, 2011 BV 3 Portfolio Company Portola Pharmaceuticals and Biogen Idec Announce Global Collaboration | Download PDF version
Oct 05, 2011 BV 4 Portfolio Company Valeritas Announces $150 Million Financing
Jul 25, 2011 BV 4 Portfolio Company Nevro Corp Closes $58 Million in New Financing
Jul 20, 2011 BV 4 Portfolio Company Epizyme and Collaborators Publish Paper in CANCER CELL | Download PDF version
May 24, 2011 BV 3 Portfolio Company Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study | Download PDF version
May 24, 2011 BV 3 Portfolio Company Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis | Download PDF version
Mar 30, 2011 BV 4 Portfolio Company Nevro Appoints Michael DeMane President and Chief Executive Officer | Download PDF version
Mar 10, 2011 BV 4 Portfolio Company Epizyme Enters Worldwide Strategic Partnership with Eisai for Cancer Therapeutics Targeting EZH2 Epigenetic Enzyme | Download PDF version
Feb 01, 2011 BV 4 Portfolio Company iPierian and Kyoto University, IPS Academia Japan Announce Global Licensing and Patent Assignment Agreement
Jan 10, 2011 BV 4 Portfolio Company Epizyme Announces Strategic Alliance to Develop Epigenetic Therapeutics | Download PDF version
Jan 07, 2011 BV 4 Portfolio Company 23andMe Announces Additional Investment in Series C Financing
Dec 08, 2010 BV 1 and BV 4 Portfolio Company Valeritas Receives FDA 510(k) Clearance for the V-Go� Disposable Insulin Delivery Device
Dec 01, 2010 BV5 Portfolio Company Verastem Highlighted in December 1 Boston Globe article "Focus Turns to Cancer Stem Cells"
Nov 19, 2010 BV 5 Portfolio Company Verastem Secures $16 Million in Series A Financing for Novel Cancer Stem Cell Drugs
Sep 21, 2010 BV 5 Portfolio Company Rhythm Closes $40 Million Series A Financing | Download PDF version
Sep 17, 2010 BV 4 Portfolio Company iPierian named by FierceBiotech as One of the "Fierce 15" Biotech Companies of 2010
Sep 08, 2010 BV 4 Portfolio Company iPierian Announces Second Close of $28 million Series B Financing
Jul 21, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals: Lilly Announces Completion of Acquisition | Download PDF version
Jul 08, 2010 BV 4 Portfolio Company iPierian Closes $22 Million Series B Financing Led By Google Ventures | Download PDF version
Jul 06, 2010 BV 2 Portfolio Company SenoRx Completes Sale to C. R. Bard | Download PDF version
Jul 02, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals to be Acquired by Lilly | Download PDF version
Jun 28, 2010 BV 4 Portfolio Company Chiasma Receives Orphan Drug Designation From The FDA | Download PDF version
Jun 28, 2010 BV 2 Portfolio Company CGI Pharmaceuticals to be Acquired by Gilead for Up to $120 Million | Download PDF version
Jun 21, 2010 BV 5 Portfolio Company Rhythm announces RM-493 Reverses Obesity and Insulin Resistance in Obese Primates
Jun 14, 2010 BV 4 Portfolio Company Chiasma announces successful oral delivery of a peptide in a clinical trial and plans to initiate a pivotal trial by year end | Download PDF version
May 20, 2010 BV 5 Portfolio Company Neurotherapeutics Pharma Closes $43 Million Series B Financing and Adds Four New Investors | Download PDF version
May 05, 2010 BV 2 Portfolio Company SenoRx to be Acquired by C. R. Bard for Approximately $213 Million | Download PDF version
Apr 30, 2010 BV 4 Portfolio Company iPierian Awarded Basic Biology Grant by California Institute of Regenerative Medicine to Study Cellular
Apr 01, 2010 BV 3 & BV 4 Portfolio Company Xanodyne and Ferring Announce Co-Promote for Zipsor
Mar 29, 2010 BV 4 Portfolio Company Epizyme Expands Leadership Team, Appointing Robert Gould, Ph.D. as CEO and Jason Rhodes as EVP and CBO
Mar 15, 2010 BV 3 Portfolio Company Portola Pharmaceuticals and Merck Announce Results of Phase 2 Study of Betrixaban
Mar 15, 2010 BV 5 Portfolio Company Rhythm Announces $21 Million Series A | Download PDF version
Mar 02, 2010 BV 3 Portfolio Company CombinatoRx Achieves $40 Million Milestone | Download PDF version
Feb 25, 2010 BV 4 Portfolio Company Alnara Pharmaceuticals Expands Leadership Team and Scientific Advisory Board (pdf) | Download PDF version
Jan 29, 2010 First iPierian (a BV4 Portfolio Company) Patent for Induced Pluripotent Stem Cell Technology Granted by the United Kingdom Intellectual Property Office | Download PDF version
Jan 28, 2010 MPM BV4 leads $35mm Series B financing for Alnara Pharmaceuticals
Jan 26, 2010 Paper entitled �Protein Methyltransferases as Target Class for Drug Discovery� by BV4 Portfolio Company Epizyme Scientists published in Nature Reviews Drug Discovery
Jan 22, 2010 BV3 Portfolio Company Somaxon Provides Update On New Drug Application For SILENOR� For The Treatment Of Insomnia
Jan 20, 2010 Gambro announces agreement to acquire CHF Solutions, Inc., a BV1 & BV3 Portfolio Company
Jan 19, 2010 BV4 Portfolio Company Chiasma Grants Option to License Transient Permeability Enhancer (TPE) Technology for Small Molecule Products | Download PDF version
Jan 06, 2010 BV3 Portfolio Company CombinatorRx Announces Senior Management Team Changes
Dec 22, 2009 BV3 Portfolio Company Neuromed and CombinatoRx Close Merger
Dec 22, 2009 BV4 Portfolio Company iPierian Highlighted In December 17, 2009 New York Times Article
Dec 04, 2009 Proteon Therapeutics Named 2010 Technology Pioneer by the World Economic Forum | Download PDF version
Dec 02, 2009 BV4 Portfolio Company Pacira Pharmaceuticals Announces Results of Another Positive Phase III Trial in Post Operative Pain
Nov 20, 2009 BV4 Portfolio Company TriVascular, Inc. Secures $30 Million in Equity Financing
Nov 20, 2009 BV2 Portfolio Company EKR Therapeutics Named Private Company of the Year By New Jersey Technology Council
Nov 20, 2009 ABC News Segment on BV4 Portfolio Company iPierian
Nov 12, 2009 BV4 Portfolio Company Peplin Acquired By LEO Pharma | Download PDF version
Nov 09, 2009 BV4 Portfolio Company NeoVista, Inc. Announces Initial VIDION� Shipments | Download PDF version
Nov 06, 2009 BV4 Portfolio Company NeoVista�, Inc. Completes Enrollment in Pivotal CABERNET� Study
Nov 05, 2009 BV2 Portfolio Company Biovitrum AB to Purchase Drug Company Swedish Orphan | Download PDF version
Nov 03, 2009 BV4 Portfolio Company EKR Therapeutics Receives Notice of Patent Allowance for Ready-to-Use Cardene� I.V. Bags
Nov 03, 2009 BV4 Portfolio Company Epizyme Appoints Hoyoung Huh, MD, Ph.D., Chairman of the Board of Directors
Oct 21, 2009 BV4 Portfolio Company iPierian To Collaborate with Johns Hopkins University on $3.7 Million NIH Grand Opportunities Grant
Oct 08, 2009 BV4 Portfolio Company Epizyme Closes $32 Million Series B Financing
Sep 17, 2009 BV4 Portfolio Company iPierian Featured In Forbes Magazine Article, October 5, 2009 Issue: "Growing Diseases In A Dish�
Sep 10, 2009 BV3 Portfolio Company Quatrx Announces Positive Results Of Second Pivotal Phase 3 Clinical Study | Download PDF version
Sep 07, 2009 BV2 Portfolio Company PrimeraDx closes $20m Series C
Sep 03, 2009 LEO Pharma to Acquire BV3 & BV4 Portfolio Company Peplin for US$287.5m | Download PDF version
Aug 24, 2009 BV2 & BV3 Portfolio Company EGS Announces Initiation of Clinical Study to Demonstrate Efficacy of StomaphyX for Revisional Weight Loss Surgery
Jul 09, 2009 Merck & Co., Inc. and BV3 Portfolio Company Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, | Download PDF version
Jul 08, 2009 iZumi Bio and Pierian Merge to form BV4 Portfolio Company iPierian to Advance Cellular Reprogramming | Download PDF version
Jul 08, 2009 CEO of BV2 Portfolio Company AVEO Pharmaceuticals discusses testing strategies
Jul 07, 2009 BV3 Portfolio Company Somaxon Pharma PIPEs $6 Million
Jul 02, 2009 Four MPM companies listed in the �Fierce 15� for 2009
Jul 02, 2009 BV3 Portfolio Company Neuromed and CombinatoRx Sign Merger Agreement | Download PDF version
Jun 25, 2009 Howard Weisman, Chairman & CEO of BV4 Portfolio Company EKR Therapeutics, Named Ernst & Young Entrepreneur Of The Year� 2009 Award Winner For The New Jersey Pharmaceutical Industry | Download PDF version
Jun 17, 2009 BV3 & BV4 Portfolio Company Xanodyne Receives Approval From the U.S. Food and Drug Administration for ZIPSOR� (diclofenac potassium) Liquid Filled Capsules
Jun 17, 2009 BV3 Portfolio Company Neuromed Announces Sale of U.S. Rights to Drug Candidate to Exgalgo� to Mallinckrodt | Download PDF version
Jun 11, 2009 Proteon Founders Named Entrepreneurs Of The Year� 2009 Award Winners in the Central Midwest Region | Download PDF version
Jun 05, 2009 BV3 & BV4 Portfolio Company Xanodyne Announces New President/CEO and Completes $38 million equity financing | Download PDF version
Jun 01, 2009 BV1 & BV4 Portfolio Company Valeritas Announces Appointment of New CEO
May 29, 2009 Proteon Therapeutics Completes Second Closing of Equity Financing | Download PDF version
May 26, 2009 BV2 Portfolio Company Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company | Download PDF version
Mar 31, 2009 BV3 Portfolio Company Quatrx Completes Enrollment of Ophena� - Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy | Download PDF version
Mar 30, 2009 BV2 & BV3 Portfolio Company EGS Announces Publication of Cadiere's TIF Study 2-Year Results | Download PDF version
Mar 23, 2009 BV3 Portfolio Company Neuromed Announces Exalgo Extended-Release Tablets Meets Primary Efficacy Endpoint in Pivotal Phase 3 Trial | Download PDF version
Mar 19, 2009 BV4 Portfolio Company NeoVista, Inc. Closes $18 million Series �D� Preferred Venture Financing Round | Download PDF version
Mar 12, 2009 European Commission Approves ReFacto AF(TM) as a Variation to the Refacto(R) Marketing Authorisation | Download PDF version
Mar 09, 2009 BV4 Portfolio Company Solasia - First Drug Trial Initiated in Japan (pdf) | Download PDF version
Mar 05, 2009 Proteon Therapeutics Completes $38M Equity Financing | Download PDF version
Feb 23, 2009 Novartis and BV3 Portfolio Company Portola ink potential $575M deal | Download PDF version
Jan 16, 2009 BV3 Portfolio Company Peptimmune grants Novartis exclusive option to license PI-2301 for multiple sclerosis | Download PDF version
Jun 11, 2008 Ipsen to Acquire BV3 Portfolio Company Tercica | Download PDF version
May 13, 2008 MPM Invests in India CRO BV4 Portfolio Company SAI ADVANTIUM | Download PDF version
Apr 15, 2008 BV4 Portfolio Company Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam® | Download PDF version
Mar 31, 2008 MPM Capital and NEA Finance BV4 Portfolio Company TriVascular2 | Download PDF version
Mar 24, 2008 Robert Millman and Dr. Elizabeth Stoner join MPM Senior Investment Team | Download PDF version
Mar 10, 2008 BV4 Portfolio Company EKR Raises over $145 million | Download PDF version
Dec 12, 2007 BV3 & BV4 Portfolio Company Peplin reports Phase IIa AK data | Download PDF version
Nov 12, 2007 BV4 Portfolio Company NeoVista data on Wet AMD presented at AAO | Download PDF version
Oct 01, 2007 Perkin Elmer to Acquire BV1 & BV2 Portfolio Company ViaCell | Download PDF version
Aug 03, 2007 BV3 Portfolio Company Pharmathene and HAQ Merger Completed | Download PDF version
Jun 22, 2007 SkyePharma Inc. Announces Name Change to BV4 Portfolio Company Pacira Pharmaceuticals | Download PDF version
Jun 11, 2007 New York TImes: GP Luke Evnin on Medical Device Investing | Download PDF version